QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in

Merck & Co., Inc. (NYSE:MRK) Expected to Post Quarterly Sales of $12.01 Billion

Last updated on Sunday, October 18, 2020 | 2020 MarketBeat

Wall Street analysts predict that Merck & Co., Inc. (NYSE:MRK) will announce sales of $12.01 billion for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Merck & Co., Inc.'s earnings. Merck & Co., Inc. posted sales of $12.40 billion during the same quarter last year, which would indicate a negative year-over-year growth rate of 3.1%. The firm is scheduled to report its next earnings results before the market opens on Tuesday, October 27th.

On average, analysts expect that Merck & Co., Inc. will report full year sales of $47.76 billion for the current fiscal year, with estimates ranging from $47.40 billion to $48.13 billion. For the next financial year, analysts expect that the firm will report sales of $50.83 billion, with estimates ranging from $47.84 billion to $53.17 billion. Zacks' sales calculations are a mean average based on a survey of analysts that cover Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 31st. The company reported $1.37 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The business had revenue of $10.87 billion during the quarter, compared to analysts' expectations of $10.52 billion. During the same quarter in the previous year, the business earned $1.30 EPS. The company's revenue for the quarter was down 7.6% on a year-over-year basis.

A number of analysts have recently issued reports on the company. Morgan Stanley reiterated a "buy" rating and set a $89.00 target price on shares of Merck & Co., Inc. in a report on Tuesday, June 23rd. Goldman Sachs Group upgraded Merck & Co., Inc. from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $91.00 to $105.00 in a report on Monday, August 3rd. Berenberg Bank started coverage on Merck & Co., Inc. in a report on Tuesday, September 29th. They issued a "hold" rating and a $88.00 price target for the company. ValuEngine cut Merck & Co., Inc. from a "hold" rating to a "sell" rating in a report on Thursday, October 1st. Finally, SVB Leerink upped their price target on Merck & Co., Inc. from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of "Buy" and an average price target of $95.08.

Shares of NYSE:MRK opened at $79.83 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.32. Merck & Co., Inc. has a 1 year low of $65.25 and a 1 year high of $92.64. The stock has a market capitalization of $201.91 billion, a P/E ratio of 19.47, a PEG ratio of 2.10 and a beta of 0.43. The stock has a 50-day simple moving average of $83.27 and a 200-day simple moving average of $80.42.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a $0.61 dividend. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date of this dividend was Monday, September 14th. Merck & Co., Inc.'s payout ratio is 47.01%.

In related news, EVP Frank Clyburn sold 18,876 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $81.55, for a total transaction of $1,539,337.80. Following the sale, the executive vice president now directly owns 99,639 shares of the company's stock, valued at approximately $8,125,560.45. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sanat Chattopadhyay sold 10,380 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $83.01, for a total value of $861,643.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 280,529 shares of company stock worth $22,761,633. Corporate insiders own 0.28% of the company's stock.

Several hedge funds have recently bought and sold shares of MRK. Public Employees Retirement Association of Colorado raised its position in shares of Merck & Co., Inc. by 3.2% during the 1st quarter. Public Employees Retirement Association of Colorado now owns 2,591,741 shares of the company's stock valued at $199,409,000 after acquiring an additional 79,468 shares in the last quarter. State Street Corp grew its stake in Merck & Co., Inc. by 0.7% during the 1st quarter. State Street Corp now owns 117,343,358 shares of the company's stock worth $9,098,570,000 after buying an additional 849,474 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in Merck & Co., Inc. by 8.3% during the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 2,963,475 shares of the company's stock worth $228,010,000 after buying an additional 227,059 shares during the last quarter. AXA grew its stake in Merck & Co., Inc. by 22.2% during the 1st quarter. AXA now owns 2,165,848 shares of the company's stock worth $166,641,000 after buying an additional 393,632 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Merck & Co., Inc. by 10,893.5% during the 1st quarter. Tower Research Capital LLC TRC now owns 8,465 shares of the company's stock worth $652,000 after buying an additional 8,388 shares during the last quarter. 73.18% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Stocks That Risk-Averse Investors Can Buy Now

If the title of this presentation piqued your interest, then you understand that there’s no such thing as risk-free investing. And that’s particularly true when you’re investing in stocks. The truth is sometimes the best thing that can happen is that your portfolio performs less badly than the market.

The goal of the risk-averse investor is not to avoid stocks, it’s to ensure that you retain the capital you gain, even if that means your portfolio does not grow as fast or as far as more aggressive stocks. You have to have a very low FOMO (fear of missing out) level.

With that in mind, there are still ways you can profit from this market without throwing caution to the wind. One is to look for stocks that have a low beta. Beta is a measure of a stock’s volatility in comparison to the rest of the market. A stock with a beta of 1, for example, means that investors can expect the price movement of the stock to be closely correlated to the market. A beta of more than 1 means the stock price will be more volatile (higher highs but lower lows).

What you’re looking for is a beta of less than 1. This means that the stock is less volatile than the broader market. While this may mean lower highs, it also generally means lower lows.

And many of these stocks are in defensive sectors. This means that their performance is consistent under both good and bad economic conditions.

View the "7 Stocks That Risk-Averse Investors Can Buy Now".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.